

Rapid urine-based screening tests increase the yield of same-day tuberculosis diagnoses among patients living with advanced HIV disease

Wake, Rachel M.^{a,b,c}; Govender, Nelesh P.^{a,c,d,e,f}; Omar, Shaheed V.^{e,g,h}; Ismail, Farzana^{g,h}; Tiemessen, Caroline T.^{e,i}; Harrison, Thomas S.^{a,b,d}; Jarvis, Joseph N.^{j,k}

^aInstitute for Infection and Immunity, St George's University of London

^bClinical Academic Group in Infection and Immunity, St George's University Hospital NHS Foundation Trust, London, UK

^cCentre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses (CHARM), National Institute for Communicable Diseases, a Division of the National Health Laboratory Service (NHLS), Johannesburg, South Africa

^dMRC Centre for Medical Mycology, University of Exeter, Exeter, UK

^eFaculty of Health Sciences, University of the Witwatersrand, Witwatersrand

^fDivision of Medical Microbiology, University of Cape Town, Cape Town

^gDepartment of Medical Microbiology, University of Pretoria, Pretoria

^hCentre for Tuberculosis

ⁱCentre for HIV & STIs, National Institute for Communicable Diseases, a Division of the NHLS, Johannesburg, South Africa

^jDepartment of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK

^kBotswana Harvard AIDS Institute Partnership, Gabarone, Botswana.

Correspondence to Rachel M. Wake, St George's University of London, Cranmer Terrace, London SW17 0RE, UK. Tel: +44 0 2087251255; e-mail: rmwake@gmail.com

Abstract

Objective: Investigation of the diagnostic yield of urine-based tuberculosis (TB) screening in patients with advanced HIV disease.

Design: A cross-sectional screening study

Setting: HIV outpatient clinics and wards at two hospitals in Johannesburg, South Africa, between June 2015 and October 2017.

Participants: Two hundred and one patients living with advanced HIV disease (CD4⁺ T-lymphocytes <100 cells/μl) attending healthcare facilities following cryptococcal antigen (CrAg) screening.

Intervention: Screening for TB using sputum for microscopy, culture, and Xpert MTB/Rif and urine for lipoarabinomannan (LAM) and Xpert Ultra.

Main outcome measures: Proportion of positive results using each testing modality, sensitivity, and specificity of urine-based testing compared with culture, and survival outcomes during 6 months follow up.

Results: Urine was obtained from 177 of 181 (98%) participants and sputum from 91 (50%). Urine-based screening increased same-day diagnostic yield from 7 (4%) to 31 (17%). A positive urine test with either LAM or Xpert Ultra had 100% sensitivity (95% confidence interval, 59–100%) for detecting culture-positive TB at any site. Patients with newly diagnosed TB on urine-based screening were initiated on treatment and did not have excess mortality compared with the remainder of the cohort.

Conclusion: Urine is an easily obtainable sample with utility for detecting TB in patients with advanced HIV disease. Combining urine and sputum-based screening in this population facilitates additional same-day TB diagnoses and early treatment initiation, potentially reducing the risk of TB-related mortality. Urine-based as well as sputum-based screening for TB should be integrated with CrAg screening in patients living with advanced HIV disease.

Keywords: AIDS; diagnostic techniques and procedures; lipoarabinomannan; point-of-care systems; tuberculosis

Introduction

Rapid detection of opportunistic infections, such as cryptococcal disease and tuberculosis (TB), is essential among patients with advanced HIV disease ^[1]. Screening (irrespective of symptoms) for TB and cryptococcosis is recommended for this population due to the risk of early or subclinical infection and immune reconstitution inflammatory syndrome (IRIS) following antiretroviral therapy (ART) ^[1]. Cryptococcal antigen (CrAg) screening and preemptive antifungal treatment reduces mortality in patients with low CD4⁺ T-lymphocyte counts (CD4⁺ cell counts) ^[2,3], and has been widely implemented using lateral flow assays (LFAs) ^[4–6]. Point-of-care methods for diagnosing TB are also available; however, only urine lipoarabinomannan (LAM) is currently recommended for screening those with low CD4⁺ cell counts irrespective of symptoms ^[7].

GeneXpert molecular testing platforms (Cepheid, Sunnyvale, California, USA) can be used for near-patient TB testing, providing results within 2 h. However, reliance on sputum samples limits their value in patients with low CD4⁺ cell counts, who are more likely to have disseminated disease and difficulty producing sputum. Sputum induction increases the risk of nosocomial transmission of TB, is poorly tolerated, costly, and not always successful ^[8].

Several studies demonstrate the utility of testing urine for mycobacterial DNA using GeneXpert assays ^[9,10], and for LAM, using LFAs such as the Determine TB LAM (Alere, Waltham, Massachusetts, USA) ^[11,12]. However, evidence from high burden countries

indicates that neither is widely used for TB screening among patients with advanced HIV disease ^[13,14].

To determine the incremental same-day diagnostic yield of screening urine for TB among HIV-positive adults with CD4⁺ cell counts less than 100 cells/ μ l, we performed LAM and Xpert MTB/Rif Ultra on urine, in addition to sputum-based tests. We estimated diagnostic accuracy of urine-based tests compared with TB culture, and report mortality rates following TB diagnoses.

Materials and methods

TB screening was carried out among participants of a prospective CrAg screening study described elsewhere ^[15]. HIV-positive adults with CD4⁺ cell counts less than 100 cells/ μ l were invited to participate during inpatient or outpatient attendance at two hospitals in Johannesburg, South Africa between June 2015 and October 2017. Patients with asymptomatic cryptococcal antigenaemia, and CrAg-negative patients with similar CD4⁺ cell counts (1: 2 ratio) were consecutively enrolled if they provided consent. Ethical approvals were obtained from the University of the Witwatersrand and the London School of Hygiene and Tropical Medicine.

A detailed TB history was obtained from interview and clinical records. All participants were tested for TB using pre and/or postinduction sputum Xpert MTB/Rif, smear microscopy (auramine stain) and liquid culture (BACTEC MGIT, Becton Dickinson, Franklin Lakes, New Jersey, USA). Urine was tested using LAM (Determine) and Xpert Ultra (FDA unapproved use). Results were available immediately for urine LAM (performed at point-of-care by research staff), and within 24 h for sputum Xpert MTB/Rif and microscopy (performed at a reference laboratory). Culture results were reported when positive within 42 days. Urine Xpert Ultra tests were performed retrospectively on stored frozen and thawed samples [median volume 11.5 ml; inter-quartile range (IQR), 11–13 ml], following centrifugation at 3000 *g* for 15 min, and suspension of the pellet in 1 ml of phosphate-buffered saline. Urine samples that were positive using Xpert Ultra were also tested using the Xpert MTB/Rif platform. Patients who tested positive for TB on sputum or urine testing were referred to TB clinics for further management. New TB diagnoses (using routine investigations instigated by participants' usual clinicians), and survival during 6 months were recorded.

The number of new TB diagnoses made on the same day as testing (by urine LAM or urine/sputum Xpert) was determined. Sensitivity and specificity of urine-based tests were estimated compared to a reference standard of TB culture, in those who had culture performed on any sample. The effect of newly diagnosed TB on mortality was estimated using Cox regression, adjusting for baseline CD4⁺ cell count.

Results

Two hundred and one participants were enrolled in the study (Supplementary Figure 1, <https://links.lww.com/QAD/C449>, Tables 1, <https://links.lww.com/QAD/C450> and 2, <https://links.lww.com/QAD/C451>). Twenty (10%) were taking TB treatment and excluded from further analysis. Of the remaining 181 participants, median age was 39 years (IQR, 33–

48), 48% were women, median CD4⁺ cell count was 36 cells/ μ l (IQR, 13–62), 26 (14%) were already taking ART, and 29 (16%) were inpatients. Fifty-nine patients were CrAg-positive and 122 CrAg-negative.

Urine and sputum samples were requested from all participants; sputum induction was attempted when equipment was available in 114 (63%). Urine samples were obtained from 177/181 (98%) and sputum from 91/181 (50%). Of 114 participants undergoing attempted induction, 39 (34%) were unable to produce sputum. Tissue samples for histology and culture were available from 8 (4%) patients within 2 weeks of enrolment.




Fig. 1: Venn diagram to show yield of same-day tuberculosis diagnoses using each test.

Thirty-one (17%) participants were newly diagnosed with TB at enrolment (Fig. 1); 17% (10/59) CrAg-positive individuals and 17% (21/122) CrAg-negative individuals. Sputum Xpert MTB/Rif was positive in seven individuals (three sputa also AFB positive). Urine testing yielded an additional 24 TB diagnoses [positive using LAM only (19), Xpert Ultra only (2), or both urine tests (3)]. All individuals with TB diagnosed by sputum testing were also positive using urine. There was no difference in the rates of positive urine-based tests between

CrAg-positive and CrAg-negative participants. Twelve (50%) individuals with TB diagnosed using urine tests alone were unable to produce sputum. One individual who was unable to produce sputum had a positive urine Xpert Ultra result, with a *rpoB* mutation. On repeat testing of Xpert Ultra positive urine samples, five of 10 (50%) were positive using the Xpert MTB/Rif platform. Antituberculous medication was started in 28 of 31 (90%) participants following diagnosis; no treatment was documented for three participants who were lost to follow up.

One hundred (55%) participants had mycobacterial cultures performed on any sample obtained concurrently (Table 1). Restricting analysis to these participants, urine LAM had a sensitivity of 71% [95% confidence interval (95% CI), 19–96] and specificity of 87% (95% CI, 77–94). Testing urine using Xpert Ultra had a sensitivity of 71% (95% CI, 29–96) and a specificity of 99% (95% CI, 92–100). A positive urine test with either LAM or Xpert Ultra had a sensitivity of 100% (95% CI, 59–100) and specificity of 86% (95% CI, 75–92) (Table 1). Specificity was likely underestimated due to the poor sensitivity of TB culture in this population. Sensitivity of urine-based tests remained at 100% (95% CI, 66–100) and specificity increased to 90% (95% CI, 83–95) using a composite of culture, histology, and PCR of sputum or any tissue as the reference standard. Two patients with positive urine LAM but negative urine Xpert Ultra, had nontuberculous mycobacteria (NTM) identified in sputum samples, without evidence of TB co-infection.

Table 1 - Sensitivity and specificity of the urine Xpert ultra, urine LAM, or of either urine Xpert ultra or LAM test positive, compared with culture^a for TB of any sample within 2 weeks of the urine test.



	Sensitivity (n/d, %, 95% CI)	Specificity (n/d, %, 95% CI)
Urine Xpert Ultra	^b 5/7, 71% (29–96)	68/69, 99% (92–100)
Urine LAM	^c 5/7, 71% (29–94)	67/77, 87% (77–94)
Urine -based test (either urine Xpert Ultra or urine LAM)	7/7, 100% (59–100)	60/70, 86% (75–93)

CI, confidence interval; d, denominator; LAM, lipoarabinomannan; n, numerator; Xpert Ultra, Xpert MTB/Rif Ultra assay.

^aOne hundred participants had samples obtained for culture: 90 sputa [seven had additional lymph node, blood, cerebrospinal fluid (CSF), and bone marrow (BM) samples]; six blood; one skin biopsy; two BM; one CSF.

^bUrine Xpert Ultra was positive in five patients with positive TB cultures (three sputum, two blood cultures), and negative in two patients with positive sputum cultures.

^cUrine LAM was positive in five patients with positive TB cultures [five sputum (one also lymph node), one blood culture], and negative in two patients with positive TB cultures (one sputum, one blood).

During 6 months follow up, 22 of 181 (12.1%) participants died; five of 31 (16%) with newly diagnosed TB at enrolment, and 17 of 150 (11%) who were negative following TB screening. Same-day diagnosis of TB (including by urine-based screening) was not significantly associated with mortality on unadjusted analysis or following adjustment for CD4⁺ cell count (adjusted hazard ratio 1.52, 95% CI, 0.55–4.17). Although there were no cases of cryptococcal meningitis in 122 patients who were CrAg-negative at enrolment, there were an additional 7 (5%) TB diagnoses during follow up, occurring at a median of 61 (IQR 43–111) days.

Discussion

Screening individuals with advanced HIV disease using urine LAM and Xpert Ultra in addition to sputum testing increased same-day detection of active TB by over fourfold, from 4 to 17%. Using both tests had 100% sensitivity compared with TB culture. A new diagnosis of TB following screening was not found to be associated with an increased risk of death in our analysis. This is in contrast to the high risk of death associated with a diagnosis of TB previously reported among patients with advanced HIV disease [16,17], and consistent with findings of the STAMP trial, which found a reduced risk of death among hospitalized patients with CD4⁺ cell counts less than 100 cells/ μ l who were tested for TB with LAM and urine Xpert MTB/Rif, in addition to sputum Xpert MTB/Rif (adjusted odds ratio 0.72, (95% CI, 0.53–0.98) [19].

Uptake of the Determine LAM for TB screening has been limited due to reports of relative low sensitivity compared with culture [18] (56% (41–70%) in patients with CD4⁺ cell counts \leq 100 cells/ μ l [11]). However, in keeping with prior studies [11,12,19,20], we found that urine LAM was positive in a distinct group of patients with negative sputum cultures, or who were sputum-scarce. The reported poor performance of urine LAM compared with largely sputum-based diagnostics may therefore underestimate its potential benefit. Furthermore, a novel assay using two high-affinity mAbs to LAM epitopes (Fujifilm SILVAMP TB LAM, Tokyo, Japan) has been developed with higher sensitivity than the Determine LAM [22–24], offering greater potential for implementation as a screening tool.

Urine LAM can be detected in patients with NTM, leading to false-positive results [25]. In our study, NTM disease likely accounted for two of 28 (7%) patients initially diagnosed with TB on the basis of a positive urine LAM result. This highlights the importance of thorough investigation of urine LAM-positive patients using TB culture and molecular diagnostics of obtainable samples including urine.

As with LAM, Xpert sensitivity in urine is greater in severely immunocompromised patients [9,10], and identifies a distinct patient group as compared to sputum-based testing [8,10,21]. The Xpert Ultra platform has greater sensitivity than Xpert MTB/Rif on sputum [26,27] and CSF [28] samples. We found urine Xpert Ultra was positive in twice as many patients compared with Xpert MTB/Rif, two of whom were negative using other point-of-care tests, and one with undetected drug resistance.

Our study selected patients on the basis of CrAg status, and may therefore represent a biased sample. However, we found that active TB was equally common in both CrAg-positive and CrAg-negative patients (Supplementary Table 1, <https://links.lww.com/QAD/C450>). In addition, our results are consistent with previous studies showing increased yield of same-day TB diagnoses using urine in addition to sputum samples. In Malawi and Mozambique, the use of LAM increased diagnostic yield in ambulatory patients by 34.6% compared with sputum Xpert MTB/Rif [29]. In South Africa, using Xpert MTB/Rif for urine as well as sputum yielded an additional 69 of 139 (50%) TB diagnoses within 24 h of admission to hospital [8]. Screening hospitalized HIV-positive patients with LAM and urine Xpert MTB/Rif diagnosed an additional 125 (60%) patients with TB in addition to those diagnosed using sputum Xpert MTB/Rif [21] in South Africa and Malawi.

Patients with advanced HIV disease are at risk of TB and cryptococcal-related mortality, but diagnosis is challenging. Urine provides a readily available sample for TB screening that can be used in addition to blood CrAg screening in patients with advanced HIV disease. This approach identified all patients at risk of cryptococcal disease and many cases of TB on the same day as testing, allowing early treatment initiation and reduced risk of IRIS. Rapid urine-based diagnostics are particularly useful in this group; many are sputum-scarce, disseminated TB is more likely and early ART initiation key. A combined screening approach, utilizing newer more sensitive diagnostics for TB on urine, as well as sputum samples should be integrated with CrAg screening for patients living with advanced HIV disease.

Acknowledgements

Sample collection, point-of-care testing, and data collection were performed by Neo Legare, Matshediso Mkhwanazi, Siphwe Kutta, and Tracey Shabangu.

R.W. designed and led study and drafted manuscript; S.O., F.I., C.T., N.G., T.H., J.J. involved in protocol development and reviewing and editing the manuscript.

Funding for this study was provided by Meningitis Research Foundation (grant awarded to R.W., 1604.0). J.N.J. is also funded by the National Institute for Health Research (NIHR) through a Global Health Research Professorship (RP-2017-08-ST2-012) using UK aid from the UK Government to support global health research. NPG was partially supported by a grant from the National Institutes of Health (R01AI118511).

Conflicts of interest

There are no conflicts of interest.

References

1. WHO. *Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy*. Geneva: World Health Organisation; 2017.
2. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al. **Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial**. *Lancet* 2015; 385:2173–2182.
3. Letang E, Muller MC, Ntamatungiro AJ, Kimera N, Faini D, Furrer H, et al. **Cryptococcal antigenemia in immunocompromised human immunodeficiency virus patients in rural Tanzania: a preventable cause of early mortality**. *Open Forum Infect Dis* 2015; 2:ofv046.
4. Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, et al. **Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast**. *Emerg Infect Dis* 2014; 20:45–53.

5. Hansen J, Slechta ES, Gates-Hollingsworth MA, Neary B, Barker AP, Bauman S, et al. **Large-scale evaluation of the immunomycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid.** *Clin Vaccine Immunol* 2013; 20:52–55.
6. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. **Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis.** *Clin Infect Dis* 2011; 53:1019–1023.
7. WHO operational handbook on tuberculosis Module 3: Diagnosis: rapid diagnostics for tuberculosis detection. <https://www.who.int/publications-detail-redirect/who-operational-handbook-on-tuberculosis-module-3-diagnosis—rapid-diagnostics-for-tuberculosis-detection>. [Accessed 3 June 2021].
8. Lawn SD, Kerkhoff AD, Burton R, Schutz C, van Wyk G, Vogt M, et al. **Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa.** *BMC Med* 2015; 13:192.
9. Peter JG, Theron G, Muchinga TE, Govender U, Dheda K. **The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce.** *PLoS One* 2012; 7:e39966.
10. Lawn SD, Kerkhoff AD, Vogt M, Wood R. **High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay.** *J Acquir Immune Defic Syndr* 2012; 60:289–294.
11. Lawn SD, Kerkhoff AD, Vogt M, Wood R. **Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study.** *Lancet Infect Dis* 2012; 12:201–209.
12. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, et al. **Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients.** *Eur Respir J* 2012; 40:1211–1220.
13. Singhroy DN, MacLean E, Kohli M, Lessem E, Branigan D, England K, et al. **Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers.** *Gates Open Res* 2020; 4:24.
14. Cazabon D, Suresh A, Oghor C, Qin ZZ, Kik SV, Denkinger CM, et al. **Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?.** *Eur Respir J* 2017; 50:1700918.
15. Wake RM, Govender NP, Omar T, Nel C, Mazanderani AH, Karat AS, et al. **Cryptococcal-related mortality despite fluconazole preemptive treatment in a cryptococcal antigen screen-and-treat program.** *Clin Infect Dis* 2019; 70:1683–1690.

16. Manabe YC, Nonyane BAS, Nakiyingi L, Mbabazi O, Lubega G, Shah M, et al. **Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda.** *PLoS One* 2014; 9:e101459.
17. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. **Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.** *Trop Med Int Health* 2007; 12:929–935.
18. World Health Organization. *The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV.* Geneva: WHO; 2015.
19. Lawn SD, Gupta-Wright A. **Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications.** *Trans R Soc Trop Med Hyg* 2016; 110:180–185.
20. Lawn SD. **Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review.** *BMC Infect Dis* 2012; 12:103.
21. Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D, Alufandika-Moyo M, et al. **Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial.** *Lancet* 2018; 392:292–301.
22. Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, et al. **Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study.** *Lancet Infect Dis* 2019; 19:852–861.
23. Nicol MP, Schumacher SG, Workman L, Broger T, Baard C, Prins M, et al. **Accuracy of a novel urine test, Fujifilm SILVAMP tuberculosis lipoarabinomannan, for the diagnosis of pulmonary tuberculosis in children.** *Clin Infect Dis* 2020; 72:e280–e288.
24. Kerkhoff AD, Sossen B, Schutz C, Reipold EI, Trollip A, Moreau E, et al. **Diagnostic sensitivity of SILVAMP MTB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV.** *Eur Respir J* 2020; 55:1901259.
25. Nel JS, Lippincott CK, Berhanu R, Spencer DC, Sanne IM, Ive P. **Does disseminated nontuberculous mycobacterial disease cause false-positive determine B-LAM lateral flow assay results? A retrospective review.** *Clin Infect Dis* 2017; 65:1226–1228.
26. Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, et al. **Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.** *Cochrane Infectious Diseases Group, editor. Cochrane Database Syst Rev* 2019; 6:1465–1858.
27. Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jatton K. **Added Value of Xpert MTB/RIF Ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting.** *Land GA, editor. J Clin Microbiol* 2018; 57:e01717–e01718.

28. Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, et al. **Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.** *Lancet Infect Dis* 2018; 18:68–75.
29. Huerga H, Mathabire Rucker SC, Cossa L, Bastard M, Amoros I, Manhiça I, et al. **Diagnostic value of the urine lipoarabinomannan assay in HIV-positive, ambulatory patients with CD4 below 200 cells/ μ l in 2 low-resource settings: a prospective observational study.** Denkinger CM, editor. *PLoS Med* 2019; 16:e1002792.